Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2017-01-12
2019-07-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Study to Assess a Compression Device in Patients With Venous Leg Ulcers
NCT02561013
The Mechanism of Action of Unite Biomatrix in Venous Leg Ulcers
NCT00953563
Safety and Efficacy Study of ICXP007 With Compression Bandaging for the Treatment of Non-Infected Venous Leg Ulcers
NCT00232973
Compression Device Versus 4-layer Compression System
NCT00821431
Evaluation of the Efficacy of Multilayer Compression & UrgoStart Plus
NCT06007703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following randomisation the participant will be reviewed in the leg ulcer clinic on a 10 +/- 4 days basis whereby pressure monitoring will be conducted using the PicoPress® (Microlan Italia, Padua, Italy), dressings will be changed and ulcer measured with standard 1cm squared grids, and the Silhoutte® 3D wound imaging system (ARANZ Medical Ltd, Christchurch, New Zealand). Participants will also submit their daily use and pressure diary. The type of dressings applied will also be recorded as well as length of appointment.
50 participants will be recruited (aim for study duration of 12-18 months) from a consultant or nurse-led clinic at Colchester Hospital and associated outlying clinics, and participants randomised to receive either compression bandages or Juxta-Cures™ (bilateral participants will be allocated a single treatment, rather than randomisation of individual limbs). Patients with 'wet' ulcers may receive absorbent dressings under Juxta-Cures™ or compression bandaging during the study period, which will be recorded on the weekly data collection for cost analysis purposes.
At baseline, 1 month, 3 months and 6 months all participants will complete health related quality of life questionnaires. The disease specific VEINESqol/sym, and generic Euroqol-5D-5L surveys will be used, and received positive feedback regarding their content at the patient focus group.
The planned study period for the randomised-control trial is 24 weeks for each participant, but 1 year in total for patient recruitment and analysis.
This study is a feasibility study therefore has not been powered. Following this study the investigators aim to undertake a multi-centre study in collaboration with the Vascular and Endovascular Research Network (VERN), powered to venous ulcer healing at 90% power, using the results of this feasibility study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Juxta-Cures™
Patients randomised to the Juxta-Cures™ device. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
Juxta-Cures™
Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
PicoPress®
Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
Silhoutte® 3D wound imaging system
Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
Standard compression
Patients randomised to standard compression. These patients will also have pressure monitoring using the PicoPress device, and ulcer imaging and surface area measurement using the Silhouette system.
Standard Compression
Compression bandaging
PicoPress®
Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
Silhoutte® 3D wound imaging system
Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Juxta-Cures™
Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
Standard Compression
Compression bandaging
PicoPress®
Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
Silhoutte® 3D wound imaging system
Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Active venous ulcer for \>2 weeks but \<1 year
* 1cm squared surface area
* Venous incompetence confirmed by clinical assessment and duplex ultrasound scan
* No evidence of arterial disease (Arterial Duplex or Ankle Brachial Pressure Index \>0.9)
* Patients able to complete trial procedures
* Patients with a life expectancy of greater than 1 year
Exclusion Criteria
* Significant arterial disease (Ankle Brachial Pressure Index \<0•9 or evidence on Arterial Duplex)
* Acute Deep Vein Thrombosis
* Patient unable or unwilling to have high compression (30mmHg minimum)
* Patients with dexterity insufficiency of hands
* Patients with peripheral neuropathy
* Leg ulcers of another underlying cause
* Leg ulcers of greater than 1 year duration
* Patients unable or unwilling to provide written, informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Colchester Hospital University NHS Foundation Trust
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam Howard
Role: PRINCIPAL_INVESTIGATOR
Colchester Hospital NHS Foundation Trust
Philip Stather
Role: PRINCIPAL_INVESTIGATOR
Colchester Hospital NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NHS Trust
Colchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Juxta-CuresTM (2016/006)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.